Original Investigations {#sec1}
=======================

 {#sec1.1}

### Concomitant Mitral Regurgitation in Patients With Chronic Aortic Regurgitation![](fx1_lrg.gif) {#sec1.1.1}
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This study examined the prevalence, mechanisms, and survival of coexistent MR in hemodynamically-significant aortic regurgitation (AR). The authors found that coexistent ≥ moderate MR occurs in 14% of patients, mostly comprising nonischemic functional mitral regurgitation (FMR) (9%), followed by organic mitral regurgitation (OMR) (5%). After 5.2 years (interquartile range: 2.2 to 10.0 years), the presence of FMR was associated with all-cause mortality independently of age, comorbidities, symptoms, left ventricular ejection fraction, left ventricular end-systolic dimension index, and aortic valve surgery. When compared with expected survival, excess mortality risks were incremental; pure AR (1.25-fold), AR + OMR (1.76-fold), and AR + FMR (2.34-fold). Therefore, both AR + OMR and AR + FMR carry a survival penalty compared with the general population, but AR + FMR is associated with the largest excess mortality and represents an advanced stage within the AR clinical spectrum.
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### Atherosclerotic Risk and Statin Use Among Patients With Peripheral Artery Disease![](fx1_lrg.gif) {#sec1.3.1}
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In the current study, the risk for atherosclerotic cardiovascular disease (ASCVD) events was higher among patients with more vascular conditions, including peripheral artery disease (PAD), coronary heart disease (CHD) and cerebrovascular disease. Among patients with the same number of vascular conditions, those with PAD had a similar risk for ASCVD events as their counterparts with CHD or cerebrovascular disease. However, patients with PAD were less likely to be taking a statin as compared to those with CHD or cerebrovascular disease. Results from the current study support the need for ASCVD risk-reduction interventions including statin therapy in patients with PAD.
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### Ramipril in High-Risk Patients With COVID-19![](fx1_lrg.gif) {#sec1.5.1}
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The use of renin-angiotensin-aldosterone system inhibitors in patients with coronavirus disease-2019 (COVID-19) or at risk is controversial. A total of 102 patients with cardiovascular disease were randomized in the RASTAVI (Renin-Angiotensin System Blockade Benefits in Clinical Evolution and Ventricular Remodeling After Transcatheter Aortic Valve Implantation) trial to ramipril (n = 50) or control (n = 52) groups. Of them, 11 patients (10.8%) developed COVID-19 up to April 1, 2020 (5 from the ramipril group and 6 from the control group), and 4 died (2 from each group). COVID-19 occurred more often in older patients, and higher body mass index was related to greater mortality. However, the use of ramipril did not affect the risk of infection or the prognosis. Hence, the use of renin-angiotensin-aldosterone system inhibitors during the COVID-19 pandemic seems safe.
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### Fewer Hospitalizations for Acute Cardiovascular Conditions During the COVID-19 Pandemic![](fx1_lrg.gif) {#sec1.7.1}
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Across an integrated tertiary care health care system, 6,083 patients experienced 7,187 hospitalizations for primary acute cardiovascular reasons from January 1, 2019, to March 31, 2020. There were 43.4% (95% confidence interval \[CI\]: 27.4% to 56.0%) fewer estimated daily hospitalizations in March 2020 compared with March 2019 (p \< 0.001). There was a significant incremental daily decline in hospitalizations of --5.9% (95% CI: --7.6% to --4.3%; p \< 0.001) in March 2020. Length of stay was shorter (4.8 \[25th to 75th percentiles: 2.4 to 8.3\] days vs. 6.0 \[25th to 75th percentiles: 3.1 to 9.6\] days; p = 0.003) in March 2020 compared with March 2019. These data substantiate concerns that acute care of cardiovascular conditions may be delayed, deferred, or abbreviated during the COVID-19 pandemic.
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### Hydroxychloroquine to Prevent Recurrent Congenital Heart Block in Fetuses of Anti-SSA/Ro-Positive Mothers![](fx1_lrg.gif) {#sec1.9.1}
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Given the irreversibility of anti-SSA/Ro-mediated congenital heart block (CHB), prevention with hydroxychloroquine (a Toll-like receptor antagonist reducing inflammation) was evaluated in high-risk pregnancies defined as mothers with a previously affected child. In an open-label prospective study, mothers received 400 mg daily of HCQ prior to completion of gestational week 10 and were followed for the primary outcome of 2° or 3° CHB. In total, 4 of 54 evaluable pregnancies resulted in a primary outcome (7.4%; 90% confidence interval: 3.4% to 15.9%), a reduction of \>50% compared with the historical rate of 18%. These results suggest that hydroxychloroquine be prescribed to prevent the recurrence of CHB.
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### Precision Health Analytics With Predictive Analytics and Implementation Research: *JACC* State-of-the-Art Review![](fx1_lrg.gif) {#sec2.1.1}
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Predictive analytics and related data science techniques expand the quality and quantity of complex data needed to inform direct patient care and public health practice. Leveraging novel implementation research methodology, predictive analytics enables the development of tools and programs to assess determinants of risk and prediction of treatment outcomes for individual patients, whole communities, and populations. Four critical areas explored as necessary to foster progress in predictive analytic science include the diversity of data types, data integration across multiple domains, effectiveness in reducing harm and waste and improving predictive accuracy in both clinical and community programs, and workforce implications.
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### The Hybrid Coronary Approach for Optimal Revascularization: *JACC* Review Topic of the Week![](fx1_lrg.gif)![](fx3_lrg.gif)![](fx4_lrg.gif) {#sec2.2.1}
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Percutaneous coronary intervention (PCI) offers low risk of immediate complications, and coronary artery bypass graft (CABG) offers improved long-term, event-free survival. Hybrid coronary revascularization (HCR) combines both, reducing invasiveness while providing a left internal mammary artery to the left anterior descending artery. This step is usually performed first, followed by stents for non--left anterior descending artery lesions. HCR reduces bleeding, ventilator time, and length of stay compared with traditional CABG. The large-scale National Heart, Lung, and Blood Institute--sponsored, randomized Hybrid Trial (Hybrid Coronary Revascularization Trial) was stopped for suboptimal enrollment. Appropriately powered randomized trials are thus required to evaluate the outcomes and cost-effectiveness of HCR compared with CABG and multivessel PCI alone.
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The Fontan procedure has improved the survival and quality of life for patients with single ventricle physiology. Chronic kidney disease is common after the Fontan operation. Elevated central venous pressure, lower cardiac output, and peri-operative acute kidney injury are the chief contributors to the pathophysiology of renal dysfunction in this population. Creatinine-based equations may overestimate the glomerular filtration rate in individuals with a Fontan circulation. Cystatin C provides a more reliable estimation of glomerular filtration rate and may predict adverse outcomes. Longitudinal assessment of renal function is needed to understand the morbidity and mortality burden of Fontan-associated renal disease.
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